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INTRODUCTION
Photodynamic therapy (PDT) was first introduced to 
treat esophageal cancer in the early 1980s [1]. When 
a clinical trial of PDT for the treatment of superficial 
esophageal cancer using porfimer sodium and a 630-nm 
wavelength excimer dye laser demonstrated a notewor-
thy result [2], PDT was approved as a palliative therapy 
for superficial esophageal cancer in 1994 in Japan and 
2005 in Korea, and for the palliative management of ad-
vanced esophageal cancer by the Food and Drug Admin-
istration in the United States of America in 1995. 
Despite the many advantages of PDT including se-
lectivity and minimal invasiveness, drawbacks resulted 
in a reduction of its application in gastrointestinal (GI) 
diseases. Like many therapeutic approaches, PDT does 
not allow for histologic examination of target lesions, 
which can be used to assess cancer invasion. In addition, 
without appropriate dosimetry, it can cause stricture in 
the GI tract. When used with Photofrin (Pinnacle Bio-
logics, Chicago, IL, USA), the earliest and first approved 
photosensitizer, prolonged and potentially severe skin 
and ocular phototoxicity can occur. Endoscopic resec-
tion including endoscopic submucosal dissection (ESD) 
and endoscopic mucosal resection (EMR) have become 
popular and are standard treatments for superficial ear-
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ly GI neoplasia [3]. 
So the question arises: is PDT an outdated technique? 
Although the role of PDT as a curative treatment has 
diminished, it is still widely used as a palliative and sal-
vage treatment because it is minimally invasive, has high 
selectivity for cancer, and has good patient compliance 
due to the simplicity of the procedure. Advanced PDT 
technologies that are easier to deliver to local lesions, in-
corporate nanoparticles, and involve new photosensitiz-
ers and light sources have been developed. One attribute 
of PDT is that the majority of photosensitizers current-
ly being used are fluorescent; this enables imaging to 
occur during therapy. Recently, this attribute has been 
exploited significantly. With these new developments 
PDT, in combination with improvements in endoscop-
ic equipment, may be used to treat diverse GI diseases.
In this review, we summarize previously reported uses 
of PDT in GI diseases and introduce more recent clini-
cal applications. 
PRINCIPLES AND MECHANISMS
PDT is a well-established clinical modality that uses 
light energy to destroy dysplastic and malignant lesions. 
It requires three core elements: light of a specific wave-
length, oxygen molecules, and a photosensitizer. A pho-
tosensitizer is a molecule that can absorb light energy 
and transfer that energy to adjacent oxygen molecules, 
which initiate a photodynamic reaction by forming 
cytotoxic molecular species including reactive oxygen, 
namely singlet oxygen [4]. Because the photosensitizer is 
preferentially localized to target tumor cells, and areas 
of light illumination can be controlled, this photody-
namic reaction primarily damages the neoplastic lesion 
and preserves the adjacent normal tissue. 
The GI tract starts at the mouth and ends at the anus. 
Most GI cancers occur at the mucosa layer, the most ex-
posed part of the GI wall. With the development of flex-
ible endoscopy, light energy can be directly delivered to 
a malignant lesion in the GI tract. This has made PDT 
popular as a minimally invasive local treatment modal-
ity for GI cancer [5]. Combined with imaging for dosim-
etry and demarcation, the potential for its use is even 
greater [6].
ESOPHAGEAL CANCER
PDT has been used as an endoscopic ablative technique 
to eliminate Barrett’s esophagus (BE) and, to a limited 
degree, high-grade dysplasia. This technique has result-
ed in regression and, in some cases, complete reversal 
of BE [7-10]. Since then, some studies of patients with 
esophageal dysplasia and cancer have reported that 
complete remission (CR) can be achieved in superficial 
lesions using PDT (Table 1) [11-19]. Studies on the use 
of PDT for esophageal squamous cell carcinoma (SCC) 
confined to the mucosal layer have suggested that PDT 
can be used as an alternative to esophagectomy given 
the low risk of lymph node metastasis in these patients. 
The majority of the patients included in the study had 
serious co-morbidities precluding surgical resection. 
Previous studies showed that the overall survival (OS) 
of patients with mucosal esophageal SCC treated with 
PDT was similar to that of patients who underwent 
esophagectomy [20,21]. There were no major compli-
cations and treatment-related deaths. Compared with 
endoscopic resection, PDT has a low complication rate, 
is simpler to perform, and is not limited by the size or 
circumference of the lesion. Given these results, PDT 
appears to be an ideal alternative to surgical or endo-
scopic resection in patients who have serious comorbid-
ities and large or multifocal superﬁcial SCC that cannot 
be completely resected endoscopically.
Recent studies have indicated a beneficial role for 
PDT in salvage treatment for locoregional failures af-
ter definitive chemoradiotherapy (CRT) for esophageal 
cancer. When locally remnant lesions are found after 
CRT, salvage esophagectomy should be preferentially 
considered as the curative treatment option. However, 
the approach has been associated with higher rates of 
postoperative mortality and morbidity compared with 
planned esophagectomy [22]. Although EMR may be an 
alternative treatment in these cases, it is limited to su-
perficial lesions and the procedure requires highly ex-
perienced endoscopists. On the other hand, PDT can be 
used for superficial cancers and for palliation of more 
advanced esophageal SCC. In a retrospective study of 37 
consecutive local failure patients treated with salvage 
PDT using porfimer sodium, CR occurred in 22 patients 
(59.5%), the 5-year progression-free survival (PFS) rate 
was 20.7%, and the OS rate was 36.1% during a median 
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follow-up period of 55 months [12]. Another large-scale 
study of 113 patients who showed local failure limited 
to within T2 after CRT reported respective PFS and OS 
rates of 22.1% and 35.9%, but a 1.8% rate of treatment-re-
lated death [16]. Talaporfin sodium is a second-gener-
ation, rapidly cleared photosensitizer that is expected 
to have less phototoxicity compared with porfimer so-
dium. In a phase I study, five out of nine patients with 
local failure after CRT achieved CR following PDT [11]. It 
is particularly noteworthy that phototoxicity and other 
severe adverse events were not observed. 
PDT has also been used for palliative treatment of 
patients with completely or partially obstructing esoph-
ageal cancer. Two randomized controlled trials were 
done to compare PDT with Nd:YAG thermal ablation for 
palliation of dysphagia in advanced esophageal cancer 
[23,24]. Both therapies had, overall, equal efficacy in im-
proving dysphagia, but PDT yielded a more prolonged 
duration of response. Another retrospective analysis was 
done on 250 patients who received multimodal palliative 
treatment, including PDT, for inoperable esophageal 
cancer [18]. In this study, if PDT was used as an initial 
therapy, the median survival was 50.9 months compared 
to 17.3 months if other options (endoscopic dilatation, 
endoluminal brachytherapy, external radiation, chemo-
therapy, stenting, feeding tube, or palliative resection) 
were used initially.
CHOLANGIOCARCINOMA
Cholangiocarcinoma (CCC) is difficult to diagnose early 
and usually presents at an advanced stage, which may be 
unresectable. Biliary stenting, mainly through the use 
of a self-expanding metal stent, has become the main-
stay of palliative treatment for unresectable CCC with 
malignant strictures [25]. However, preventing tumor 
ingrowth and maintaining stent patency are unresolved 
problems [26]. Palliative options available for patients 
with hilar CCC include PDT, which involves a single 
minimally invasive treatment that has a low complica-
tion rate and is well tolerated. PDT in conjunction with 
biliary stenting could be an attractive treatment because 
it reduces the local obstruction of tumor tissue by gen-
erating singlet oxygen and may result in long-term pa-
tency. 
Several uncontrolled and controlled studies compar-
ing stenting alone to stenting with PDT for unresectable 
CCC have been conducted (Table 2) [27-33]. These trials 
showed that PDT improved cholestasis and quality of 
life by diminishing the need for further procedures, 
such as stent revision and percutaneous biliary drain-
age. This results in a longer stent patency period be-
cause PDT may cause tumor “remodeling,” which can 
prolong or enhance the decompression effect. PDT was 
also associated with increased OS in patients with unre-
sectable CCC. The adverse effects of PDT were predict-
able and relatively easy to treat. Neither study report-
ed severe photosensitivity or procedure-related death. 
Thus, PDT seems to be a promising palliative treatment 
for unresectable CCC and should be considered part of 
the standard of care for these patients. 
PANCREATIC CANCER 
The survival statistics for pancreatic cancer (PanCa) re-
main dismal and the mainstay for PanCa treatment is 
surgery. For patients with non-resectable disease, the 
outlook is even more dismal. PDT can play a significant 
role in the management of patients with non-resectable 
disease. There have been two reports on the use of PDT 
for palliation of non-resectable PanCa [34,35]. While the 
two studies used different photosensitizing agents, both 
had promising results. The benchmark for tumor ne-
crosis was met in both cases. In a study with verteporfin, 
one patient reverted to being resectable and underwent 
an R0 Whipple procedure [34]. Combined with other 
therapeutics and nanomedicine, PDT has great poten-
tial for PanCa treatment.
GASTRIC CANCER
The outcome of gastric cancer patients has dramatically 
improved due to advancements in the accuracy of diag-
nostic endoscopy, and a decrease in the invasiveness of 
endoscopic therapies such as EMR and ESD. However, 
in patients with a background of intestinal metaplasia, 
it is still difficult to detect malignant lesions and eval-
uate the resection margin. Fluorescence navigation by 
photodynamic diagnosis (PDD) using 5-aminolevulinic 
5Lee HH, et al. Photodynamic therapy for gastrointestinal disorders
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acid (ALA) can provide good visualization of gastric ma-
lignant lesions to determine the extent of the lesions. 
ALA is a naturally occurring amino acid and an early 
intermediate in the heme biosynthesis pathway. Orally 
administered ALA is mainly incorporated into malig-
nant cells and metabolized to a photodynamically active 
protoporphyrin IX that emits a red fluorescence upon 
excitation with blue light [36]. The major advantage of 
ALA is that it is rapidly metabolized, significantly reduc-
ing the period of cutaneous photosensitivity.
Several studies have demonstrated that ALA-mediated 
PDD is a promising tool for diagnosing minute lesions 
and peritoneal metastasis in gastric cancer. A Japanese 
study showed that laser-based endoscopy detected upper 
GI tumors as red fluorescent navigation (PDD-positive) 
in 23 of 27 lesions [37]. Interestingly, all but one of the 
intestinal type carcinomas were significantly PDD-posi-
tive, whereas signet ring cell carcinomas were PDD-neg-
ative. To evaluate the detection of peritoneal metastasis 
in gastric cancer, ALA-PDD was added to conventional 
diagnostic laparoscopy for 52 advanced gastric cancer 
patients [38]. Using ALA-PDD, peritoneal dissemination 
was detected in five of 24 patients with no macroscop-
ic evidence of peritoneal metastases on white light. In 
another study, staging laparoscopy with ALA-mediated 
PDD was performed in 13 patients with serosa-invading 
gastric cancer [39]. When PDD was used, the peritoneal 
metastasis detection rate was significantly higher than 
with white light. These results show that ALA-PDD may 
be useful for preoperative staging of advanced gastric 
cancer. 
Treatment of advanced gastric cancer, especially in se-
rosa-positive cases, has focused on preventing peritone-
al recurrence because the peritoneum is one of the most 
common recurrence sites after curative gastrectomy. Al-
though several therapeutic options, including systemic 
adjuvant chemotherapy and intraperitoneal chemother-
apy with or without hyperthermia and CRT, have been 
tried [40-42], there is no standard effective treatment to 
prevent peritoneal recurrence and significantly increase 
survival. PDT may be a good alternative treatment op-
tion because micrometastatic nodules on the perito-
neal surface and intraperitoneal floating cancer cells 
are potentially suitable PDT targets. In a study using a 
peritoneal metastasis mice model, talaporfin, another 
second-generation photosensitizer, accumulated more 
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in metastatic nodules than normal organs when inject-
ed intraperitoneally [43]. Talaporfin-mediated PDT also 
exerts considerable antitumor effects in vivo. The total 
weight of peritoneal metastatic nodules was lower in 
mice models with PDT delivered using nanoparticles 
loaded with indocyanine green. These mice also had 
significantly improved body weight loss and a higher 
survival rate [44]. These results show that PDT may be a 
promising diagnostic and therapeutic modality in peri-
toneal dissemination of gastric cancer. 
RECENT DEVELOPMENTS TO OVERCOME THE 
LIMITATIONS OF PDT
As outlined above, PDT is a very attractive treatment 
modality for cancer because it has minimal toxicity 
and can be applied repeatedly without harming adja-
cent normal tissue [45]. PDT is currently widely used to 
treat skin diseases and easily accessible malignant and 
pre-malignant lesions. 
To maximize the effect of PDT, further research is 
needed to enhance its three core elements: the photo-
sensitizer, light, and oxygen. Fig. 1 shows recent devel-
opments to overcome the limitations of PDT. 
The photosensitizer can cause hypersensitivity, aller-
gy, toxicity, and unpredictable biodistribution proﬁles 
if administrated intravenously, especially in multiple 
doses. Unpredictable biodistribution can lead to the 
accumulation of photosensitizer in easily light-exposed 
uninvolved tissues such as the eyes and skin, and this 
can result in phototoxicity and prolonged photosen-
sitivity when patients are exposed to ambient light. 
Local delivery of the photosensitizer may solve these 
problems. Local delivery may shorten treatment time, 
enhance therapeutic efficacy, and eliminate skin photo-
sensitization completely. There are several approaches 
for the local delivery of PDT to target GI tumors; these 
include spraying via the working channel of the endo-
scope, intratumoral injection, and the use of photosen-
sitizer-coated stents. 
To enhance the clinical use of PDT, the second chal-
lenge is to improve the targeting of the drug-activating 
light to the target tissue. In PDT, superficial tissues can 
be easily illuminated using convenient light sources, but 
deep tissue tumors are more difficult for light to pene-
trate. For example, blue light (400 to 450 nm) penetrates 
approximately 1 mm into tissue, while orange light (590 
to 620 nm) penetrates approximately 1.5 mm, and red 
light (620 to 750 nm) penetrates even further, up to 3 mm 
[46]. Newer light sources, such as light-emitting diodes 
(LEDs), are being explored to deliver light more effec-
tively. LEDs can generate high-energy light of desired 
wavelengths and can be assembled in a range of geom-
etries and sizes [47,48]. During PDT, monitoring tumor 
tissue oxygenation, by measuring the partial pressure of 
oxygen and the level of hypoxia markers, may be used to 
increase the concentration of singlet oxygen to the tar-
get tissue during light irradiation. In addition, fraction-
ating light irradiation by controlling light/dark periods 
can promote tissue oxygen re-perfusion to compensate 
for oxygen depletion caused by photochemical reactions 
[49,50].
Figure 1. Recent developments and future perspectives with 
regard to improving the efficacy of photodynamic therapy 
(PDT) to treat gastrointestinal tract cancers. EUS, endoscop-
ic ultrasound; LED, light-emitting diode. 
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NOVEL APPLICATIONS OF PDD AND PDT IN GI 
MALIGNANCY
Much research has been done to extend the application 
of photodynamic techniques to the early diagnosis and 
treatment of GI malignancy. 
In the spotlight in the field of GI endoscopy is molec-
ular imaging because it can be used to detect lesions at 
an early stage. Molecular imaging can be used to visu-
alize the molecular fingerprint of target cells, and not 
just their gross morphology. Developments in molecu-
lar imaging are occurring with advances in new imaging 
techniques such as virtual chromoendoscopy and mag-
nifying endoscopy. In molecular imaging, disease-spe-
cific biomarkers are targeted using fluorescently labeled 
exogenous molecular probes including antibodies, an-
tibody fragments, peptides, nanoparticles, and activat-
able probes [51]. Combining a molecular probe with a 
photosensitizer can enhance tumor targeting and the 
detection of minute lesions by the endoscopist. Fur-
thermore, it can enable optical biopsy and theragnosis, 
which combines simultaneous diagnosis and therapeu-
tics. In our group, a peptide specific to colon cancer 
was isolated using phage display and then conjugated 
to hematoporphyrin (HPP), a promising second-gener-
ation photosensitizer [52]. Immunocytochemical stain-
ing using fluorescein isothiocyanate or HPP-conjugated 
peptides showed high binding affinity to colon cancer 
cell lines. The HPP-conjugated cancer-specific peptide 
showed an enhanced PDT effect, compared with HPP 
alone. These results show that targeted PDT using pep-
tide probes may constitute promising candidate treat-
ments for use in the development of colon cancer diag-
nostics and treatments.
Photosensitizer-embedded stents allow for repeatable 
intraluminal PDT, which leads to regression of sur-
rounding GI malignant tissue and extends stent paten-
cy. A recent study of a polymeric photosensitizer (pul-
lulan acetate-conjugated pheophorbide A)-embedded 
self-expanding nonvascular metal stent, which permits 
repeatable PDT of CCC without systemic injection of 
the photosensitizer, reported that the stent sustained its 
PDT effects for at least 2 months in vitro [53]. Further-
more, in vivo testing using HCT-116 tumor-xenograft 
mouse models showed degradation of tumor cells and 
regression of xenograft tumors after laser exposure. 
PDT can improve the tissue penetration efficiency (PE%) 
of released drugs in non-vascular drug-eluting stents 
(DESs) by breaking the epithelial layer with singlet ox-
ygen, a process called photochemical tissue penetration 
(PTP). We developed a PTP-DES with a photosensitiz-
er (chlorin e6) incorporated in a gemcitabine-eluting 
polyurethane membrane [54]. This stent demonstrated 
a 2-fold increase in the PE% of gemcitabine, and tumor 
growth was effectively inhibited in an in vivo mouse 
model. Our results indicate that the PTP-DES system 
has great potential for improving the therapeutic effect 
of conventional DES.
Nanomedicine that combines PDT with molecular 
target therapy may be used to enhance the efficacy of 
anticancer treatments and improve outcomes for pa-
tients with highly treatment-resistant GI malignancy, 
while decreasing toxicity. Recently, we developed a novel 
photoactivatable multi-inhibitor nanoliposome (PMIL), 
which consists of a nanoliposome doped with a photo-
sensitizer (benzoporphyrin derivative) in the lipid bi-
layer, and a nanoparticle encapsulating cabozantinib, a 
multikinase inhibitor [55]. This novel nanoscale drug not 
only causes photodynamic damage to tumor cells and 
microvessels but also initiates the release of cabozan-
tinib inside the tumor. In a mouse model of PanCa, 
PMIL resulted in prolonged tumor reduction and me-
tastasis suppression. These results open the door to the 
application of PDT in tumor-selective chemotherapy.
CONCLUSIONS
We reviewed a number of key studies that used PDT to 
treat GI malignancy. Drawbacks of PDT including sub-
optimal efficacy, phototoxicity, and high cost have cur-
tailed the initial enthusiasm for this procedure in treat-
ing GI malignancy. PDT still has a role as a palliation 
and salvage treatment because it is a minimally invasive 
procedure. Much effort has been put into widening the 
application of PDT, and favorable results in areas such 
as early diagnosis, salvage treatment for local failures, 
and palliation of GI cancer, are shedding new light on 
the applications of PDD and PDT. Novel integration of 
PDT with existing technologies such as molecular im-
aging, DES, and nanotechnology may make PDT a feasi-
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ble and desirable option for the treatment of GI cancers.
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